ganoderic acid D: isolated from Ganoderma lucidum; structure in first source [MeSH]
| ID Source | ID |
|---|---|
| PubMed CID | 102004379 |
| MeSH ID | M0521454 |
| Synonym |
|---|
| ganoderic acid d |
| AC-34453 |
| ganoderic-acid-d |
| 108340-60-9 |
| AKOS037515103 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| lanosterol | 14alpha-methyl steroid; 3beta-sterol; tetracyclic triterpenoid | bacterial metabolite; human metabolite; mouse metabolite; plant metabolite; Saccharomyces cerevisiae metabolite | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| ganodermic acid s | triterpenoid | 2009 | 2009 | 15.0 | high | 0 | 0 | 0 | 1 | 0 | 0 | ||
| ganoderic acid h | 2011 | 2011 | 13.0 | high | 0 | 0 | 0 | 0 | 1 | 0 | |||
| ganoderic acid a | 2011 | 2011 | 13.0 | high | 0 | 0 | 0 | 0 | 1 | 0 | |||
| ganoderic acid b | 2011 | 2011 | 13.0 | high | 0 | 0 | 0 | 0 | 1 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cancer of Colon | 0 | 2018 | 2018 | 6.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Cancer of Esophagus | 0 | 2020 | 2020 | 4.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Colonic Neoplasms | 0 | 2018 | 2018 | 6.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Esophageal Neoplasms | 0 | 2020 | 2020 | 4.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Esophageal Squamous Cell Carcinoma | 0 | 2020 | 2020 | 4.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| Sensitivity and Specificity | 0 | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| Article | Year |
|---|---|
| Proteomics characterization of the cytotoxicity mechanism of ganoderic acid D and computer-automated estimation of the possible drug target network. Molecular & cellular proteomics : MCP, , Volume: 7, Issue:5 | 2008 |
| Article | Year |
|---|---|
| Pharmacokinetics of ganoderic acid D and its main metabolite by liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, , Jul-01, Volume: 930 | 2013 |
| Article | Year |
|---|---|
| Pharmacokinetics of ganoderic acid D and its main metabolite by liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, , Jul-01, Volume: 930 | 2013 |